Cargando…

Immunohistochemical-based molecular subtyping of colorectal carcinoma using maspin and markers of epithelial-mesenchymal transition

The aim of the present study was to classify colorectal carcinoma (CRC) into molecular subtypes, based on immunohistochemical (IHC) assessments. A total of 112 CRC samples were molecularly classified based on the expression levels of epithelial-mesenchymal transition (EMT)-associated IHC markers. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Banias, Laura, Jung, Ioan, Bara, Tivadar, Fulop, Zsolt, Simu, Patricia, Simu, Iunius, Satala, Catalin, Gurzu, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956164/
https://www.ncbi.nlm.nih.gov/pubmed/31966075
http://dx.doi.org/10.3892/ol.2019.11228
_version_ 1783487097414352896
author Banias, Laura
Jung, Ioan
Bara, Tivadar
Fulop, Zsolt
Simu, Patricia
Simu, Iunius
Satala, Catalin
Gurzu, Simona
author_facet Banias, Laura
Jung, Ioan
Bara, Tivadar
Fulop, Zsolt
Simu, Patricia
Simu, Iunius
Satala, Catalin
Gurzu, Simona
author_sort Banias, Laura
collection PubMed
description The aim of the present study was to classify colorectal carcinoma (CRC) into molecular subtypes, based on immunohistochemical (IHC) assessments. A total of 112 CRC samples were molecularly classified based on the expression levels of epithelial-mesenchymal transition (EMT)-associated IHC markers. A total of three molecular subtypes were defined: Epithelial, membrane positivity for E-cadherin and β-catenin, negative for vimentin; mesenchymal, E-cadherin-negative, nuclear β-catenin- and vimentin-positive; and hybrid cases, epithelial tumor core and mesenchymal tumor buds. Most of the cases were diagnosed as moderately differentiated adenocarcinoma (n=89; 79.46%). The majority of cases (n=100; 89.28%) exhibited a mismatch repair proficient status (microsatellite stable CRCs). A predominance of epithelial-type (n=51; 45.54%) and hybrid CRCs (n=47; 41.96%) was observed, whereas a few cases (n=14; 12.50%) were classified as mesenchymal-type CRCs. This molecular classification was associated with pathological stage (P<0.01), pT stage (P=0.04), pN stage (P<0.01), the grade of tumor budding (P=0.04), and maspin expression in both the tumor core (P=0.04) and the invasion front (P<0.01). The mesenchymal-type cases predominantly exhibited lymph node metastases, high-grade budding and a tendency towards maspin nuclear predominance. All epithelial-type cases with maspin-only expression (n=18) were non-metastatic. Patients with CRC of the epithelial subtype and those with a lymph node ratio (LNR) ≤0.15 presented the best overall survival, followed by those with hybrid and mesenchymal subtypes. Nuclear maspin positivity was more frequent in cases with a high-budding degree compared with those with a low-budding degree (P=0.03). The EMT-associated molecular classification of CRCs may be used to identify the most aggressive CRCs, which show a mesenchymal phenotype, high-budding degree, maspin nuclear positivity and lymph node metastases. The pN stage, LNR and budding degree of patients, which can be evaluated with maspin expression, remain the most important prognostic factors.
format Online
Article
Text
id pubmed-6956164
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-69561642020-01-21 Immunohistochemical-based molecular subtyping of colorectal carcinoma using maspin and markers of epithelial-mesenchymal transition Banias, Laura Jung, Ioan Bara, Tivadar Fulop, Zsolt Simu, Patricia Simu, Iunius Satala, Catalin Gurzu, Simona Oncol Lett Articles The aim of the present study was to classify colorectal carcinoma (CRC) into molecular subtypes, based on immunohistochemical (IHC) assessments. A total of 112 CRC samples were molecularly classified based on the expression levels of epithelial-mesenchymal transition (EMT)-associated IHC markers. A total of three molecular subtypes were defined: Epithelial, membrane positivity for E-cadherin and β-catenin, negative for vimentin; mesenchymal, E-cadherin-negative, nuclear β-catenin- and vimentin-positive; and hybrid cases, epithelial tumor core and mesenchymal tumor buds. Most of the cases were diagnosed as moderately differentiated adenocarcinoma (n=89; 79.46%). The majority of cases (n=100; 89.28%) exhibited a mismatch repair proficient status (microsatellite stable CRCs). A predominance of epithelial-type (n=51; 45.54%) and hybrid CRCs (n=47; 41.96%) was observed, whereas a few cases (n=14; 12.50%) were classified as mesenchymal-type CRCs. This molecular classification was associated with pathological stage (P<0.01), pT stage (P=0.04), pN stage (P<0.01), the grade of tumor budding (P=0.04), and maspin expression in both the tumor core (P=0.04) and the invasion front (P<0.01). The mesenchymal-type cases predominantly exhibited lymph node metastases, high-grade budding and a tendency towards maspin nuclear predominance. All epithelial-type cases with maspin-only expression (n=18) were non-metastatic. Patients with CRC of the epithelial subtype and those with a lymph node ratio (LNR) ≤0.15 presented the best overall survival, followed by those with hybrid and mesenchymal subtypes. Nuclear maspin positivity was more frequent in cases with a high-budding degree compared with those with a low-budding degree (P=0.03). The EMT-associated molecular classification of CRCs may be used to identify the most aggressive CRCs, which show a mesenchymal phenotype, high-budding degree, maspin nuclear positivity and lymph node metastases. The pN stage, LNR and budding degree of patients, which can be evaluated with maspin expression, remain the most important prognostic factors. D.A. Spandidos 2020-02 2019-12-18 /pmc/articles/PMC6956164/ /pubmed/31966075 http://dx.doi.org/10.3892/ol.2019.11228 Text en Copyright: © Banias et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Banias, Laura
Jung, Ioan
Bara, Tivadar
Fulop, Zsolt
Simu, Patricia
Simu, Iunius
Satala, Catalin
Gurzu, Simona
Immunohistochemical-based molecular subtyping of colorectal carcinoma using maspin and markers of epithelial-mesenchymal transition
title Immunohistochemical-based molecular subtyping of colorectal carcinoma using maspin and markers of epithelial-mesenchymal transition
title_full Immunohistochemical-based molecular subtyping of colorectal carcinoma using maspin and markers of epithelial-mesenchymal transition
title_fullStr Immunohistochemical-based molecular subtyping of colorectal carcinoma using maspin and markers of epithelial-mesenchymal transition
title_full_unstemmed Immunohistochemical-based molecular subtyping of colorectal carcinoma using maspin and markers of epithelial-mesenchymal transition
title_short Immunohistochemical-based molecular subtyping of colorectal carcinoma using maspin and markers of epithelial-mesenchymal transition
title_sort immunohistochemical-based molecular subtyping of colorectal carcinoma using maspin and markers of epithelial-mesenchymal transition
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956164/
https://www.ncbi.nlm.nih.gov/pubmed/31966075
http://dx.doi.org/10.3892/ol.2019.11228
work_keys_str_mv AT baniaslaura immunohistochemicalbasedmolecularsubtypingofcolorectalcarcinomausingmaspinandmarkersofepithelialmesenchymaltransition
AT jungioan immunohistochemicalbasedmolecularsubtypingofcolorectalcarcinomausingmaspinandmarkersofepithelialmesenchymaltransition
AT barativadar immunohistochemicalbasedmolecularsubtypingofcolorectalcarcinomausingmaspinandmarkersofepithelialmesenchymaltransition
AT fulopzsolt immunohistochemicalbasedmolecularsubtypingofcolorectalcarcinomausingmaspinandmarkersofepithelialmesenchymaltransition
AT simupatricia immunohistochemicalbasedmolecularsubtypingofcolorectalcarcinomausingmaspinandmarkersofepithelialmesenchymaltransition
AT simuiunius immunohistochemicalbasedmolecularsubtypingofcolorectalcarcinomausingmaspinandmarkersofepithelialmesenchymaltransition
AT satalacatalin immunohistochemicalbasedmolecularsubtypingofcolorectalcarcinomausingmaspinandmarkersofepithelialmesenchymaltransition
AT gurzusimona immunohistochemicalbasedmolecularsubtypingofcolorectalcarcinomausingmaspinandmarkersofepithelialmesenchymaltransition